UK Biotech Booms But Will It Ever Produce A Big Player?
Investment From US On The Rise
Executive Summary
Any chance that Kymab would advance to become a fully integrated biopharma has gone with Sanofi's deep pockets turning the heads of investors. Is the UK ever likely to develop its own Amgen or Moderna?
You may also be interested in...
India’s Top Deck Backs Patent Box Policies, Four-Prong Strategy
C-suite executives from Sun Pharma, Zydus, Dr Reddy’s, Biocon, Piramal and Bharat Serums discuss future growth drivers as the generics opportunity shrinks. Favorable patent box policies, open-source innovation and areas like gene therapy and orphan diseases feature among ideas thrown up.
Immunocore Aims For $100m IPO After Immunotherapy Success
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.